Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. - Wikidata - awgldk - TriplyDB

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

http://www.wikidata.org/entity/Q33211563

about

IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study Adoptive immunotherapy for cancer: building on success Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunity BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination Tumor cell recognition efficiency by T cells Progress and controversies in developing cancer vaccines.CpG Oligonucleotides as Cancer Vaccine Adjuvants Trial watch: IDO inhibitors in cancer therapy The Endoplasmic Reticulum Chaperone GRP170: From Immunobiology to Cancer Therapeutics Cancer immunotherapy Broad-Spectrum Drugs Against Viral Agents Structures of MART-126/27–35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition Adjuvants for peptide-based cancer vaccines Engineering New Approaches to Cancer Vaccines Harnessing the Microbiome to Enhance Cancer Immunotherapy Early experience with novel immunomodulators for cancer treatment Carbon nanotubes as vaccine scaffolds A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites.The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo.Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen Immunogenomics and systems biology of vaccines.The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.Putting the brakes on BTLA in T cell-mediated cancer immunotherapy Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG.MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity.Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligodeoxynucleotides against ovarian cancer CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner Toll-like receptor agonists in cancer therapy.High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination.Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes Enhanced early innate and T cell-mediated responses in subjects immunized with Anthrax Vaccine Adsorbed Plus CPG 7909 (AV7909)Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses.ProtEx technology for the generation of novel therapeutic cancer vaccines An unusual case of metastatic melanoma sensitive to chemotherapy and immunotherapy, with late immune escape in the brain.IL-12 is required for mTOR regulation of memory CTLs during viral infection.

P2860

Q21245663-4E377852-7763-4E3C-A757-0E9DE3F90571 Q24546258-A50F13E5-5593-4675-A430-76913CC76D4F Q24610550-6676B446-2BCF-41EA-823E-68C647F4DD27 Q24652965-78D12BCF-9D0A-4041-9DCE-13B5A14C25F9 Q24805449-3BE24EBD-C6F5-438B-A062-3960DB97B2E5 Q24810256-0E859808-9FEA-4012-AA8D-D8C2E222C8A9 Q26783826-CF4E6D54-A003-4763-B142-D25D5AB4FAD7 Q27006866-4CBA8D64-72C2-4E6B-8E73-513DFE2AC493 Q27026256-1EFF7603-6CE7-4933-907C-418A771E3004 Q27026870-89664820-840B-41AC-A436-9B68525145AA Q27487859-2A87EB73-9E28-4261-9100-A15446B500F4 Q27647534-693B7C2A-21DB-4D0F-AE5C-0FBACA84B5D4 Q28072236-178AC9A5-FB50-4A32-BAF8-9BAFC521F78C Q28085563-6425ECF9-41CF-4C50-A0D5-33DB49774114 Q28088598-35C33CB3-477A-43E0-A460-6C0FC5A9ED01 Q28241744-C0B239AF-C4EE-4BA7-91E0-1118559B3B7B Q28392532-A5BFB10C-4C11-492E-B43A-EBE04F7E9142 Q30278070-6CE863B3-0063-40F4-87E7-3DEBE90605E7 Q30425111-76CFCFAF-A520-4841-8638-6C803724AC63 Q33299427-AE0448D9-7F63-4EA3-996E-913DD32CFF0A Q33322422-3A599B30-5322-49A1-8B21-40588C8FB2D0 Q33350387-CAA1AF2F-EA95-41AF-982B-A0D29F13B862 Q33451335-4A10FCD3-E6C5-4491-9BB1-CF58C1DBAF41 Q33559717-FFE1BE9A-C546-497A-B9E6-FA1405DF225C Q33586122-4B5FF1DF-76AB-471C-84C8-789F866EF776 Q33614005-01ABC15C-3826-4E0C-A26A-8B7C4F288924 Q33690978-E0C019EB-C3FC-4841-90A9-162C81F1C6B8 Q33731220-7DC1832E-0C03-4864-988E-B44944F4E3E9 Q33750205-4F84998A-B96B-4A6D-94C1-5BCA7383DA4B Q33792003-90904757-8AC1-476C-9C7B-DE3D81723C03 Q33902560-1B131C83-1471-47A5-B085-89836E83449B Q33918509-5E403DBA-54E7-4DE2-901E-AC28208E3251 Q33952837-58EB08C7-0FE7-41A7-AEDB-CA83DE6D3D93 Q33954123-94ACBF84-F106-49E3-BC3B-774CE7929A85 Q34005128-D8758F3C-011A-4591-9FB9-BD778F5556D7 Q34047191-0D077358-C426-48BA-8210-39D556A961A8 Q34048648-19BEC1A9-B20E-4915-896B-B5B2D915857D Q34048819-D408B770-F250-43EE-9287-F8A14929BCBC Q34111882-77E0AE0C-19E7-4146-865C-94F97C6993CE Q34143415-01403178-CD26-4A8D-9047-872B6CBB0877

P2860

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

http://www.wikidata.org/entity/Q33211563

description

2005 nî lūn-bûn

@nan

2005 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մարտին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@ast

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@en

type

label

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@ast

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@en

prefLabel

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@ast

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@en

P1433

Q33211563-F7FEFABF-6D63-4732-8EC5-5A6418B99777

P1476

Q33211563-AA50E409-72A4-4E4D-9078-052DB382E1AC

P2093

Q33211563-20662B59-0A3D-4F0D-993D-4A0925D0041A

Q33211563-2BF54DE2-99A6-4424-B270-EED27220B37B

Q33211563-36A1BF49-CC25-47BE-A1A7-FA7D3F58B58C

Q33211563-429FD9A4-A43E-48A3-B2F4-C9CCD98A0FA6

Q33211563-53E600F4-781B-4C0E-A58A-49CB6B1E5EC8

Q33211563-E0688CA0-2258-4AAC-9219-4BE5835D8598

Q33211563-E575E7F3-1F75-4FE1-983A-31640E2A9D25

Q33211563-EAE3935C-7745-43D4-868D-F9038F24FE90

Q33211563-EFE33E70-5502-4687-B940-5BCF81B27DD1

P2860

Q33211563-1166C6CC-0200-4590-AC66-E2E3485BAAC7

Q33211563-187D2315-85B6-4D9F-B650-792D14D364B8

Q33211563-1AAD71FA-71D4-4CDD-8A00-41BFA1046100

Q33211563-1E5103F4-3067-41BD-8858-27DA972B37BB

Q33211563-20C84181-EE94-43DB-A06D-C1073608C04D

Q33211563-30227A18-690F-480F-93C5-01C07AD61489

Q33211563-41B862E0-1787-4CE6-8A19-CC11072949C9

Q33211563-450D20AD-32BF-44FD-BAC0-2C74AB6B30DC

Q33211563-483399BA-EDE9-480D-BE82-33F9FCB87AA8

Q33211563-49C6C6AC-C12C-4F91-9C4A-FC40B8C93E6B

P304

Q33211563-BA280E33-64CC-4210-B6F2-6382B96FDBD5

P31

Q33211563-F8A60C39-D213-4468-B05F-FFADBAD32F66

P356

Q33211563-DDD56864-AB28-4ECE-ADFF-5ABADE2D8B42

P407

Q33211563-39E2F597-BFBE-48DB-8A58-6373E763375B

P433

Q33211563-999CB6C8-7891-445B-A4E5-97D529D8D93C

P478

Q33211563-ED1E3830-ABD2-4B0B-9559-92753382C36E

P577

Q33211563-94DFB9AE-7B72-4ABC-9C29-EAEA015A215C

P698

Q33211563-0A80E15C-2D8A-4E1C-93DB-4A3C274F3736

P932

Q33211563-FF25F0AE-B6E2-467E-9C7F-F406B9212F92

P356

P1433

Journal of Clinical Investigation

P1476

Rapid and strong human CD8+ T ...... CpG oligodeoxynucleotide 7909.

@en

P2093

Arthur M Krieg

http://www.w3.org/2001/XMLSchema#string

Daniel E Speiser

http://www.w3.org/2001/XMLSchema#string

Danielle Liénard

http://www.w3.org/2001/XMLSchema#string

Donata Rimoldi

http://www.w3.org/2001/XMLSchema#string

Ferdy Lejeune

http://www.w3.org/2001/XMLSchema#string

Jean-Charles Cerottini

http://www.w3.org/2001/XMLSchema#string

Nathalie Rufer

http://www.w3.org/2001/XMLSchema#string

Pedro Romero

http://www.w3.org/2001/XMLSchema#string

Verena Rubio-Godoy

http://www.w3.org/2001/XMLSchema#string

P2860

A Toll-like receptor recognizes bacterial DNA

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

Approaching the asymptote? Evolution and revolution in immunology

Phenotypic analysis of antigen-specific T lymphocytes

Toll-like receptors: critical proteins linking innate and acquired immunity

The dendritic cell system and its role in immunogenicity

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.

Ex vivo analysis of human antigen-specific CD8+ T-cell responses: quality assessment of fluorescent HLA-A2 multimer and interferon-gamma ELISPOT assays for patient immune monitoring.

P304

739-746

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI23373

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15696196

http://www.w3.org/2001/XMLSchema#string

P932

546459

http://www.w3.org/2001/XMLSchema#string